ASCO Annual Meeting | Conference

Frontline Pembrolizumab Bests Chemo in NSCLC, Especially in PD-L1-High Subgroup

June 3rd 2018

Patients with non-small cell lung cancer treated with frontline pembrolizuma lived 4 to 8 months longer than those who received standard of care chemotherapy.

Dr. Oxnard Discusses the Circulating Cell-Free Genome Atlas Study

June 3rd 2018

Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, medical oncology, Dana-Farber Cancer Institute, discusses the design and importance of the Circulating Cancer Genome Atlas (CCGA) study in an interview with OncLive during the 2018 ASCO Annual Meeting.

Dr. Costa on Triplet of Venetoclax, Carfilzomib, and Dexamethasone in Multiple Myeloma

June 3rd 2018

Luciano J. Costa, MD, PhD, associate professor of medicine, Blood and Marrow Transplantation and Cell Therapy Program, University of Alabama at Birmingham School of Medicine, discusses phase II findings with the triplet regimen of venetoclax (Venclexta), carfilzomib (Kyprolis), and dexamethasone in patients with relapsed/refractory multiple myeloma. Costa shared this insight in an interview with OncLive during the 2018 ASCO Annual Meeting.

Matched Targeted Therapy Extends Survival in Advanced Hard-to-Treat Cancers

June 2nd 2018

Personalized therapy based on tumor molecular profiling resulted in improved overall survival for patients with advanced, hard-to-treat cancers.

cfDNA Assays Demonstrate High Specificity for Early Stage Lung Cancer Detection

June 2nd 2018

Initial results from the Circulating Cell-Free Genome Atlas study strongly suggest that cell-free DNA tests can be used with a high degree of specificity to detect signs of early stage lung cancer.

Pembrolizumab Studies Show Disparate Data on Link Between AE and Response in Multiple Myeloma

June 2nd 2018

Pembrolizumab (Keytruda) yielded inconsistent results regarding the relationship between immune-related adverse events and objective response in multiple myeloma.

Microsatellite Instability Status Links to Lynch Syndrome in Broad Array of Cancers

June 2nd 2018

Microsatellite instability-high tumors are more likely to be associated with the presence of Lynch syndrome. Yet, 45% of patients with cancers not typically identified with Lynch syndrome actually qualify for germline genetic testing.

Only Modest Benefit Seen With Taselisib in PIK3CA-Mutant Breast Cancer

June 2nd 2018

Treatment with taselisib in combination with fulvestrant provided a modest progression-free survival benefit of 2 months compared with fulvestrant alone in patients with estrogen receptor–positive, PIK3CA-mutant locally advanced or metastatic breast cancer

Once Weekly Carfilzomib Superior in Relapsed/Refractory Myeloma

June 2nd 2018

Carfilzomib (Kyprolis) administered once weekly at 70 mg/m2 with dexamethasone resulted in a prolonged PFS compared with the standard twice-weekly schedule in patients with relapsed/refractory multiple myeloma.

Atezolizumab Plus Chemo Extends PFS in Frontline Squamous NSCLC

June 2nd 2018

The addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel (Abraxane) delayed the risk of progression or death by 29% compared with chemotherapy alone for patients with advanced squamous NSCLC.

LOXO-292 Shows Impressive Response Rates for RET-Positive Tumors

June 2nd 2018

The highly-selective RET inhibitor LOXO-292 demonstrated robust clinical activity across RET-altered solid tumors, including in patients with brain metastases and the RET V804M gatekeeper mutation.

Ibrutinib/Rituximab Reduces Progression Risk by 80% in Waldenstrom Macroglobulinemia

June 2nd 2018

Adding ibrutinib to rituximab lowered the risk of disease progression or death by 80% versus rituximab alone in patients with Waldenström macroglobulinemia.

bb2121 Adds Nearly 1 Year of PFS for Heavily Pretreated Myeloma

June 2nd 2018

bb2121 had a median progression-free survival of 11.8 months and a median duration of response of 10.8 months for patients with relapsed/refractory heavily pretreated multiple myeloma.

Dr. Mohile on Using a Geriatric Assessment in Older Patients With Cancer

June 2nd 2018

Supriya Gupta Mohile, MD, MS, professor of medicine and surgery, James Wilmot Cancer Institute, director, Geriatric Oncology Clinic, University of Rochester, discusses pooled findings with a geriatric assessment for older patients with cancer in an interview with OncLive during the 2018 ASCO Annual Meeting.

Dr. George on Results of Abi Race Trial in Prostate Cancer

June 2nd 2018

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses the results of the prospective multicenter Abi Race trial, which compared outcomes of African-American and Caucasian patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (Zytiga) and prednisone.

Pomalidomide Triplet Extends PFS in Relapsed/Refractory Myeloma

June 2nd 2018

Adding pomalidomide (Pomalyst) to bortezomib (Velcade) and low-dose dexamethasone reduced the risk of disease progression or death by 39% in patients with relapsed/refractory multiple myeloma with prior exposure to lenalidomide.

Venetoclax/Carfilzomib Combo Highly Effective for t(11;14) Myeloma

June 2nd 2018

The addition of venetoclax to carfilzomib and dexamethasone demonstrated a 100% objective response rate with a very good partial response or better rate of 86% for patients with relapsed/refractory t(11;14) multiple myeloma.

Colorectal Cancer Treatment Twice as Costly in US Than Canada, Despite Similar Outcomes

June 2nd 2018

A study that compared costs of treatment for metastatic colorectal cancer in Western Washington and the province of British Columbia in Canada found that prices were more than twice as high for the US patients than for their Canadian counterparts, with no significant difference in outcomes.

Geriatric Assessment Improves Patient Satisfaction, Patient-Oncologist Communication

June 2nd 2018

Evaluating health-related concerns as part of routine care for elderly patients with advanced cancer significantly improved doctor-patient communication and patient satisfaction.

Black Men May Fare Better Than White Men With Standard mCRPC Therapy

June 2nd 2018

Black men with metastatic castration-resistant prostate cancer may experience greater benefits from chemotherapy and hormone-targeting treatment than their white counterparts.